OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2026-03-31-accounts

Chaflty regl8tr•llon number 1141310 CURE CANCER UCL CANCER INSTITUTE TRUSTEES. REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026

CURE CANCER @ UCL CANCER INSTITUTE LEGAL AND ADMINISTRATIVE INFORMATION Trugte S Bagheri S Hamiltt>n N Hamilton J Margolin MBE S Sampson FCA Charlty numb•r 1141310 Prln¢lp21 addr•s8 Pltt Hou¥e 120 Bakor Streel London W1U8TU Indopondenl •x•mln•r m8ke8w0thAc￿untsnts Unll 101, First Floor Cervantes H¢)use 5-9 Headstong Road Harrow HA11PD 8ank•rn N&￿¥t Bank PIC 9 Thg Broadway Stanmore Middlesex HA7 4DA

CURE CANCER @ UCL CANCER INSTITUTE CONTENTS Pag• Tru8toes' r•port Independent examkntr8 report Staltsmenl of fln4nc4kl activ￿09 B•tan¢o 8h••l Not•8 to th• flnancl81 st#t•ment• 7-11

CURE CANCER @ UCL CANCER INSTITUTE TRUSTEES. REPORT FOR THE YEAR ENDED 31 MARCH 2026 Thtr Intsto0$ pr8s•nt th 8nnual roport and financl81818lemgnl8 for thg year ended 31 March W26. Th• chartly •l$o ¢)poral•s urKJor tho name Cure Cancer UCL Th• ffinwlal $talomonis bggn prgpar•d In accordance wlth the pth)unUng 881 out In nole I to Ih flnan¢lal slalemonts and cunply wllh the charW¥ gov&mlng document. Ihe CharfU8s Act 2011, FRS 102 Flnanaal Roporting Slondard Op￿Icabl• in Ihe UK and R8publlc of Ireland. ond th• Chèrfllès SORP 'knounlSno and Roporting by Charftle8'. Slatsmenl of Ro¢ommgnded Pracilcè 8ppli¢8ble lo chadli•s preparing thelr accounts In accord8n￿ wllh tho Flnand•l Row)￿n9 S￿ndard appllcablo In the UK and Rwibli¢ ol Ir•knd (FRS 102).. ObJ•ctI￿ and a¢tSvftle8 Cure Cenc•r UCL ex18ts lo fund ploneorlng ￿earCh Into Non-Hodgkln's Lymphi)ma. Th• ch8rfty w88 found•d by Mr8 Sandra Hamlllon and IJ ¥upport811 by Its Patrons: Prolessor Anthony Gold$tono. C8E (Unlverslty Cellege Holpltal. London),. MrAndre8 Mrchl8 (Head of tho C8ncef Unft, 8om81 General Hospllall: Rachol Stth•n8,' log•ther wlih a larytr and enthu¥Lq¥tlc cornmlttee rgpresenllng a wlde range of ages and expertenco. In further4nce ol our C￿rttable obh8thè8, thè charlty r81898 funds through donalons and •vont4 which ar• th•n 8ppll•d dlro¢tly lthvards 8UPPOrtlng r080grch eqylpmènl and 18cllltl8B 81 Unlverslty CoU•ge London IUCL). Athl•v•ffl•nl• and perfonnan Durlng the finand81 year, Ihrough a numb•r ol fundro1•lrtg events ond don8llon8, the chrlly rnI8ed 8 lotal ol £38282, Th•so lundi w•r• u••d lo purth88• eJJ•nlal •qulpmenl requlr•d by th• UCL r•J••r¢h d•￿rtrn•nt. Th• oqulpm•nl Included, bul wa8 nol Ilmllad lo,. Op•ntron8 Robot that la In8trumental to rfj8•arch In l¥ot•omlc8 R••earch Tranllallon Plarfom). Fun(trnl•lng Ev•nts Tho foll¢Jwlng fundrnwng •v•nt• ¢onlrlbulod lo our Ineomo thls y￿r s￿￿tUal Wofk8hop tt￿10d by El8lrè8 Manor Hou80 Gruft8 held alAld8nh&n So¢lal Ctub 8ponsored by P•lrn•nla Hall Marathon We remaln extremety watefvl for ihe dedlcaibn and Support of our wnmlite8, volunleern, and supr#xtsr8, ￿t￿)ut whom tho$0 •vonl8 wwkl not ￿ po8$lbh.

CURE CANCER @ UCL CANCER INSTITUTE TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2026 Flnanclal rnvl•w Thè Iruslees ¢>)nfim) that tho ¢hority r8maln8 In è st8bl8 flnandal posltlon and IhAI al funds ral8•(I w•re ap￿1•￿ wholty in accordanco wilh the charlty's tharilable objecllves. P￿11¢ B•nofft 81•tom•nt Tho trusts•8 ￿n￿mI that they have had duo Wafd to the Cherfty Comm1181on'8 guldan& on publ1¢ benoflt when pl8nnlng and r•vl•wlng Ihe ¢h8rlty'8 8etlvll•8 and oblocUve•. Th• of Curo Cancor UCLdlrgdy bon•llth tho publlc by: Fundlng ¢uMlnwdgo re8earch In￿ Non.Hodgkln'8 Lymphoma •t UCL, wlth th• of Improvlng tr•atmenl outcomes and 8urvlv81 rat¢8. Supportlng the advanc•m¢nl of medlcal sclgnce. hading lo pot•nllol breakthrough• that VAII b•ngffit c￿n￿r Ilent8 and Ihelr lamllles bolh I0￿MY 8nd glob811y. Engaglng the communlty In fundr•l8ing gdlvllle8. ra181ng aworone88 of cancar r88earch. Ind on¢our¥glng wldèr publlc partlclptlon In chadtabl• SUPPOFL In th18 way, th• Iruotw or• 8a118fl•d Ih•t th• charlty'8 d￿l￿r cl•er And tangth1• publlc b•nofiL A¢ntrhl•dg•m•nl• W• exlond our 8lnGere th•nk¥ to all commltt•8 moml)ern. coll•agLt88, donorn, and 8upport•rn who hav• ¢onlrfbut•d thelr Ime, expertl88, and oeneroslty throughout Iho yè6r. 8truclurns gov•m•no• mAnag•m•nt Cgn•tllutJ•n The charills govemlng docvmentlg Tru810o•d dat•d 7 Aprfl 2011 and *Mond￿ on 27 October2011. Tho Iru$l•os who 8•rvod durfn9 thé y•Ar and up10 the dal• of 8bn•turo of th• fin•nd81818toment8 wern.. S Bagho S Hamlllon N Hamllton J Margolln MBE S Sarnp8on FCA Tho management ofthe charfty Is the re$pon$lblllty of th• tru81ees who aro •l•ctsd and cwpt•d under the terrns of the Trust Dèad.

CURE CANCER @ UCL CANCER INSTITUTE TRUSTEES, REPORT (CONTINUED) FOR THE YEAR ENDED 31 AIARCH 2026 Th• Tru6lee6' fow1 w•$ 4K¥YOVOd by tho 8owd of TnJ61•88. S FCA 17 July 2026

CURE CANCER @ UCL CANCER INSTITUTE INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF CURE CANCER @ UCL CANCER INSTITUTE I report lo the Iruslees on my examination ol lh8 finanaal sialgm&nts ol Cure Cancer @ VCL Can￿r Inslitulo (the ¢haiityl for Ihe yeai ended 31 Mar¢h 2026. RosponBiblliUes and basss of report As the trustees ol the charity you are responsible for the preparation of the finawal statements in a¢¢orflgn¢e with the rgquir9m9nls of Ihg ChariliesAct 2011. I rgport in rospect of my oxamln8tK￿ of Ihe tharity's finanu81 ¥tstemenls carried oul undgr seclion 145 01 tho Charllles A¢1 2011. In carying oul my examination I havo fdh)wed the Directions glven by the Chaiity Comml88lon under seGI'on 14515Xbl of th6 Ch8ritiesAcl 2011. Ind•p•nd•nt •xamSnorfs st•t•mfrnt Your attention is drawn to the fact that Ihe charriy h8$ wep8red the financi&l sialements in accordance with the relovant version of the Stalem8nl of Recommended Praciice appli¢8bltr lo charrties prep8Ting Ihgir financi81 stoiements in accordance with thè Financial Reporting Stsndard applicabl8 in the UK and Republic of Ireland IFRS 1021 in preference lo the Accounllng and Reporllng by Charitles.. Stalemenl of Recommendecj Practlce issu¢d on 1 Aprll 2005 which is referred to in Ihe extanl re9￿￿tIonS bvl h8s now been ¥wthdrawn. l undetstand that this has been don8 In ordar for the financlal slal¢menls to Provide a tfU& and fair wow in a¢¢ordanc8 %wlh UK G&nerally A¢cgpled Aecounling Practicè. I have comploled my gxamination. I confirm Ihal no mgttarn have tomè to my gtionlion in o)nnfrclion with th8 gx¥rnlnatlon glvlng me cause lo believe Ihal In any materlal raspgci.. a¢¢ounllng records were nol kept in re5P8Ct of th8 charlty as requirod by 8ectlon 130 01 the Charfues Act 2011. lh finanual slal8m8nls do nol accord with Ihose rgcorfs". or lh8 financial slalgmgnt$ do nol compty wilh tho applicable fequir•mont$ conceming Ihg form and content ol naneSal slalements sel out in the chariti￿ IAccouni¥ and Reports) Regulations 2008 other than any r8quir8menl thal the fin8ndo1 siot8menis give 8 In￿ and falr view, whlch is not a mattgr ￿nSIde￿d 8$ Part 01 8n Ind•p•ndnl examlnatknn. I have no Con￿M$ and have ￿rne across no oth¢r matters in connection with Iht examination to which attention sho*Jld bè drawn in this report in order to 8nablo a proper understsnding of the financial $iatsm8nls io b& reached. gd Signgd.. S&nl8y Kumar Sah ACA. FCCA Makesworth A¢counl8nts Unll 101. Ilrsl Floor C8rvanlos House 9 Headstonè Road Harrow, HA1 1PD 0gte<l.' 17 July 2026

CURE CANCER @ UCL CANCER INSTITUTE STATEMENT OF FINANCIAL ACTIVITIES IINCLVDING INCOME AND EXPENDMJRE ACCOUNT) FOR THE YEAR ENDED 31 MARCH 2026 Unrostrlct•d UnrnBtrfct•d fvnd8 fund$ 2026 2025 Incomo from: Don81ion$ and bgaci&s Ch8ritable activltlgs Inve$tm8nts 7,556 30.706 291 8,183 31,540 85 Total Incom• 38.553 39,808 Expondltur• on: Charitable adivttles 48,1Tfj 95.492 Totsl &xpendltsr• 48,176 95.492 •xpendllurn and mov•ment In fvnds 19,6231 {SS,684) Ro¢on¢lllallon of fund8: Fund balanee5 at 1 Aprll 2025 32.665 88,349 Fund b•lan¢g8 4131 March 2026 23,042 32,065 The statomont of flnanclal aclmtles Indudes dl galn$ and10$sos recognlsed In the year. All Incomg WKI gxpendlture derive from contlnuing ¥11￿11$s.

CURE CANCER @ UCL CANCER INSTITUTE BALANCE SHEET ASAT31 MARCH 2026 2026 2025 Not•8 Current a¥Mts Dobtors Gash at bank and In hand 11 3,338 20,704 187 33.478 24.042 33,665 Credttorty: •mounts lainng duo wlthln one year 12 11.000) {1,000} Not Currnnt a81•ts 23,042 32.065 Tho funds of thè charlty Unrestrithd fund5 13 23.042 32,665 23.042 32.665 Thp finanL¥al stalgmonts were approvgd by the trusts￿ on 17 July 2026 S Samw40n FCA Tru$t8•

CURE CANCER @ UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026 A¢¢ountlng pollc1•8 Charlly Inform•tlan Curfj Cancer UCL Can￿r Instituts is è ¢harlty rogi8lered In England, r0gtstr4ti￿ number 1141310. ll8 prindpal office18 Plit House. 120 Bakei Slroel. London, W1U 6TU. 1.1 Ba•18 of pr•parallon The financlal 5tatem8nl$ have b8•n prép8red In a¢¢ordanc8 th• charW¥ govemlng document, the Charttl88 Act 2011, FRS 102 'The Flnanclol Roportlng Stsndard 8ppllcobl8 In the UK and Republi¢ of Irelar>d' and thè Ch8dlle$ SORP 'A¢countSno 8nd Repo￿ng by charl￿e$.. Statèmént of Recommended Prad app11￿ble to charflles pr8p8rfng thelr •cGounls In •c¢ordan¢• wllh th8 FlnanGlal Reportlng 8tsnd8ril appllcabla kn the UK Rybllc ol Ir8lar¢d {FRS 1021". Th• chaity l• a Publlc Benafil Entbty as (l￿ngd by FRS 102. Th• ch•rlty ho8 loken 8dvant890 of tho provl$ton8 In the SORP for I￿t to pr•parn a 8t•knenl ot cash flow8. Thè fln•neW 8tstornnl• depart•d from Ihg Charftle8 IAccount8 and Rawtsl R•gulations 2008 only lo the extent requlred lo provlda a true ond f8lr vlaw. Th18 d¢porture h88 Involved foHowlng Stalomènt of Rècomm8ndad Practlco for charllbob applylng FRS 102 r#lhor than th• vernlon of lh• Statam•nl ol Rwjmmendod Pradlco whkh IJ referred lo In the Regulallon8 btrt whl¢h h88 11n￿ been Nylthdrawn. Tho Ilnandal 8tal•monts are propared In ¥i•dlng, whSch l• th• luncllonal cLtrr•n¢y ¢1 Iho ch•rfty. Monetsry •mounl• In the88 fln4nclal 8tslam•nts Aro round•d lo tho nooro6t £. Th• fln•nclal •t•t•m•nts hav• b••n pryor•d und•r tho hl•lorlcal co8t conv•nUon.Th• prfndpal accoUn￿ng polld¢• adoptsd arn ￿ out b•low. 1.2 ¢Jolng COn￿M At Ihe tm• of aPFwovlng the flnancljl slatsm¢nts, the tru8ts88 have a reasonab￿ 8xpoclailon that thoy have •d•qu8ta re8ourc•È to ca)nllnuo In opèraltonal 8xl8t•n¢• tr Ihe fcreBee8blo fuluro. Thu8 con￿n￿O to adopl the golng concwm tsa￿8 ol a¢countlrKJ In prepgrfng the finand818tstements. la Chrltablo fund• Unrestrfded fund8 4r8 8¥8IIAble lor Use al thg dl8crellon of th8 truJtees In furtheranc8 of I￿1r charttable Ro8Mcled funds are 8ubigcl to sporjfic condhlon8 by donor• or granior8 as to how Ihoy may b• u8•d. Th• purpo808 and u8•8 olthe r•8lrteA•d lund8 ore 601 out tn lh8 nol08 to t￿ fln8ndal 8tat•m•ni8. Endowmoni fundg are 8ublecl 10 8p•¢ific condltlon• ty donorn that tho capbtsl must b• malntalnod ty th• charity. 1A In¢om• Income18 recogrA8ed when the charfty Is ￿gallY •nllded toll aft•r 8ny p•rformance c¢ndlllon# hav• b•èn m•L the amounts can be measured reliably, and li 1$ prob8bl8 that Income wlll be received. C88h donatlons are rocognised on re¢8lpt. Other don8tlon8 ar• re¢xgnls$d onc8 the charity ha8 been nollfiod of lh8 donaiion, unlèss perfomionoe ¢ondilion8 require doferral of the amounl. Income tax r•coverable In relation to donation$ received under Gift￿￿ or deeds of covenant 18 Tecognised at the time of thg don8lion. L8gad8s ar8 racognlsod on recolpl or othe￿180 If th8 chartly ha5 be&n no1￿led of an Imp8ndlng dLslrfbLrtkJn. the amount 1$ kno￿, end r9eeipt is expected. If Ihe amount Is not kn¢)wn. the legacy is Iroaled a8 a contlngont assgl.

CURE CANCER @ UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2026 A¢¢ountlng pollclos {COn￿nU•d) 1,6 Expèndlturo Exp8ndilurg is recognlsed oncè there 18 8 leg81 w constructive obli9alion lo transfer ecor￿MIe b￿&fil to Ihlrd party, It Is PFob8bl8 Ihal a transfer of ecommlc b8nofits WUI be requlrod In settloment, and the amount of tho oblig8tion be measured reliabty. Expgnditure is das8ified by actthty. Thè costs of each ac16vity arn made up of the total of dIr￿t costs and 8hared cosls, indLhdlng support Costs Involved In undertaklng each activSty. Dlrecl costs ottrlbulablg to a slngle athvlty af• allocaled dlreclly to th81 actfvtty. Shared costs whlch conlrlbute to more than ono acovlty and 8UPPOrt cos18 whith arg not atlrfbulabh lo 8 slngl8 activity arg apporuoned be￿••n those adi¥l￿S on • ba￿S eonsist8nt with tho u6e of resources. Centrd slaff costs aro allocated on tha bas18 01 time spon( and dopreciation charggs are alloced on tho portion of the assgl's use. 1.6 C•sh •nd •qulval•ntS Cash and cash 8qulvalonts IndLth cash In hand, deposits held at ¢ll wilh b8nk5, other sl)ort-lem ￿QuId Inveslmants with ortglnal maturfll88 of Ihr•o months or1688, 8nd bank overdrafts. Bank overdrafts are shown wjlhln b¢)rrowlngs In currènt Ilabll￿e9. 1.7 Fln8ncl•l Instrum•fits The tharity has elgthd to appty ts wovlsions of Secuon 11 .8881¢ Finanual Instruments, and Se¢tton 12 'Olher Fln4ndal Instruments188U•8' of FRS 102 to 011 of Its flnandal Instrumenls. Financ¢al instrument8 are recognised in th& ch8rSlYs balance sheel wh8n Ihg tharlty becomes party to lh8 contractual provlsion$ of the in8trumgnL Finanaal assets and liablli1S8s are offseL wth the net amourts prèsented in the finand81 statements. vthen Iherg is a legally enforceable rtght to sot off the reaognl$ed amounts and thorfj 1$ an inlonllon to $8ttl& on a nel basls or to re8llse the as8et artd settl8 thè Ilablllty slmuftangously. Bask flnanclal amets Baslc ffinancial assets. which indude debtOTS and cash and bank balances. are InS1ially moasure(l ai tr•nsactlon price induding transaction o)sts end are $ubsgqU8ntly COTrie(l al am¢)rtised eogt u&n9 ihe èffective inter¢$l m&thod unloss thg arrangement eonstltutO8 a ffinanung Iran$a¢lkin. where tho Iransaclion Is measured al Ihe Present value of the fvlure rocfjipts rfiscKyJnted al 8 rnad(el rate of interest. Flnancial assets das8ified as r¢ceivBNe within one year are not amorbsed. 8a$le thanelal Ilabllllles 8asic financial1Sabllilios. indudlng crgdilorn and bank kAns are Inllially recogn58ed at Iransaction price unkss the orrangemgnt tsjnsttluies a finanang tran98ction. where the d•bt In$irum8nt is measured al the Jmesent Value of the future payments dI$￿Unted 01 a market rale of Interest. Flnandal Ilabllmes dasslfigd as payable wllhln on8 year ara not amort58ed. Debt Ingtrumgnts 8ro 8ubwuonlly tsrrfèd ot am0￿sed co81. using the 8ffo¢tfve inleresl rate Ingthod. Trad¢ wditOTS are obllgatlon8 to pay for goods or servi￿& that havg been wulred In Ihe ordkngry ¢ourso of oporat10￿ from 6uppllers. Amounts payable arg thsslh8d as current Ilabllllle8 If paymnl Is due wlthln ong year or less. If nol, they ore pr8s8nt8d as n¢)n￿rrent 118bllilie& Trode credltoys aro re￿gnISed Initially al tran9actlon prlce and subseql￿n11Y measured al amortlsed cost U81ng thè 8ffecdv8 Interest method. Der￿o￿nI￿On olllnan¢l•l Ilabllltl•s Fin8ncièl liab1111195 are der8cognl$ed when the tharity'8 contractU81 obllgatk)n$ &xpTr or are di8ch8rg8d or cancelled.

CURE CANCER UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARGH 2026 Crltlul aooountlng 0ollm•t•• And ludg•m•nts In tho 8ppllco1ion of the thadty's accounting polldo8, tho tru81006 are requlred to mgke ludgemwts. 06tlmalo8 and asyumpllons about the corrying arnounl ol assfjls and Ilabililies that are not readlly apparent from oth•r 80urcfr$. Tho 08llmales ond a8soclaled assumpbons are basod on hlslorfcal expertence and olhor fa¢tors ihol are consldered to b8 relev4nL Actual results may dlff•r from Ihes• 88tlmate•. The 08Imate8 2nd und•rlylng 868umplKins arg rovlwmd on an ongolnB ba818. R•vlskins to ac¢ounting ¢8timaias 8r9 reGognlsod In tho poriod In whlch the 08llmale 18 rnVI￿d wheré thè T8vl8lon affects Lmly Ihal pe￿0d, or In the pèrfod of the revlslon and fvture p8rfodg whore th8 revl8lon affects both current Bnd ftrturo p•Aod8. l)on•llon¥ and l•gacl•8 Uftr•8trl¢t•d UnM•trl¢t•d fund• fvnd• 2020 2025 Don•Uon• and g1ft1 Gr8nl¥ ond glft 8ld dolmj 3.241 4.315 4,579 7.558 8,183 Chwlthbl• actlvltl Total fund• Total fund8 2026 2025 Evonl InL￿me 30,706 31,$40 Ineanm Irom Inv••tm•nt• Unrn8trk1￿ Unr•$tri¢t•d lund¥ 2026 2025 Inter0￿ roc•lvabl• 291 85

CURE CANCER @ UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEMEKfs (CONTINUED) FOR THE YEAR ENDED 31 AIARCH 2026 Ch•rltsble •dSvl¢l•• support of UCL can￿ In8thute Fund8 2026 Fund8 2025 Vgnug Hire Event p￿d￿ti0ft ¢Thts ststionory Ind8p8fKlgnl gxaThdnaUon tknatlon to UCL 4,769 1,2S7 1,19) 4,710 4,635 147 40.000 48,176 95,492 48,176 95,492 rmjrtng the finandal yaor. Ihe charlty made a donatitm of £40.0￿ to supwt a Tesearch pro￿ lèd by 8 doctor affiliated Ihe UCL Cancer Instittrte. The th)nati￿ was speificaty de6ign8kn1 to advance cancer research In Ilng ¥￿th Ihe obje￿1¥89. Not mmm•nt In funds 2025 The nel movem•nt ts) Is 8talod alr chargW(¢rdltry).' 8tatsm8nts 1,000 Tru•t• l)Jrry the year. IM) tn￿te•S received any r0munernt￿ or other berth {2025: £NIL). the year erxled 31 Mgrth 2026, no trustse exp?￿eS have b88n ￿￿urrod (2(Y25'. £NIL). Empbye 2026 Muffl￿r Numb•r The charity has Tr) ernF4oyees and its kty managerr￿1 pwsomel lh8 tr￿leaS (2025. the same). 10 T•x4tlon Thg d￿rity is 8x8mpl from laxatiry) on its because ￿ ils is 8PF4ied for (tsitatrlg IXMPD56S. 10-

CURE CANCER @ UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEMEKrn (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2026 11 I)￿10￿ 2025 AM•urt¥ f•lllng duo wlllAn on• y•r. Other debtors PrepayM￿tr 8fKI tsx reco￿8￿48 187 187 12 Crodltor8: •mounM faRlng du• wlthln 2025 1.000 13 Unre•trlcled fvnds unrestrhxed fvnds tharty CAW1￿ the urwended bala￿e$ oldonatkns and grants TtJth are subj￿1 to spe0f￿ con¢kn lry donorn ar#J granltys as to may b8 used. These indude designated fvrKls vthich have boon sot 8%dè tyJtof unr85trirt•l funds by ts trusto9$ for SWC purpoBes, A11Apr In¢omlng Ro8our¢o8 At 31 MaKh 202S règour¢e# expendod 202e Genwal furnts 32.665 (48.176) 23,042 Pr•vlou• y•ar: At 1 Aprl hKomlng R¢•wr￿ Al 31 Ma￿h 2025 General lunds 195.492) 32,685 14 R•lal•d party transathnB 11